ClinicalTrials.Veeva

Menu

Tiotropium / Respimat One-Year Study

Boehringer Ingelheim logo

Boehringer Ingelheim

Status and phase

Completed
Phase 3

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Other: Placebo
Drug: Tiotropium Inhalation Solution

Study type

Interventional

Funder types

Industry

Identifiers

NCT00168831
205.255

Details and patient eligibility

About

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

Enrollment

1,007 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Criteria

  • Patients with stable moderate to severe COPD and a smoking history of at least 10 pack years were eligible for inclusion in the study. Patients with significant diseases other than COPD were excluded as were patients with a recent history of myocardial infarction, history of malignancy, unstable or life-threatening cardiac arrhythmia, narrow-angle glaucoma, asthma or other allergic conditions. Patients treated with cromolyn, nedocromil, oral beta-adrenergics or unstable doses of oral corticosteroids were ineligible for inclusion in the study as were patients who had received previous treatment with tiotropium.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

1,007 participants in 3 patient groups

Tiotropium Respimat 5mcg (Tio R5)
Other group
Treatment:
Drug: Tiotropium Inhalation Solution
Tiotropium Respimat 10mcg (Tio R10)
Other group
Treatment:
Drug: Tiotropium Inhalation Solution
Placebo
Other group
Treatment:
Other: Placebo

Trial contacts and locations

78

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems